-+ 0.00%
-+ 0.00%
-+ 0.00%

InfuSystem Expects 2026 Pro Forma Revenue Growth of 6%-8%

PUBT·11/09/2026 23:17:12
InfuSystem Expects 2026 Pro Forma Revenue Growth of 6%-8%
  • InfuSystem forecasts 2026 pro forma revenue growth of 6%-8%, with an adjusted EBITDA margin in the low-to-mid 20% range.
  • The long-term adjusted EBITDA margin target is 22%-25%, versus 22.9% for the trailing 12 months through September 30, 2026.
  • Completed infrastructure investments, improved billing efficiency and growth in less capital-intensive therapies are expected to support margin expansion.
  • 2025 revenue reached $143.4 million, up 6%; adjusted EBITDA rose 25% to $31.5 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InfuSystem Holdings Inc. published the original content used to generate this news brief on November 09, 2026, and is solely responsible for the information contained therein.